GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide, liraglutide, tirzepatide and others have emerged as powerful tools not just for weight loss, but for overall metabolic, cardiovascular, and long-term health. At Preston Wellness, we guide patients through evidence-based care: choosing the right medication, monitoring safety, and integrating lifestyle changes for durable results.
What Are GLP-1 Receptor Agonists?
GLP-1 (glucagon-like peptide-1) is a hormone naturally secreted by the gut in response to food. It helps regulate blood sugar by:
- Increasing insulin secretion after meals
- Reducing glucagon release
- Slowing gastric emptying (so you feel full longer)
- Reducing appetite via action in the brain
Medications in this class mimic these effects. Some are approved for type 2 diabetes; higher doses are approved for obesity even without diabetes.
Efficacy: What Research Shows
Numerous randomized controlled trials (RCTs) and meta-analyses have demonstrated:
| Medication | Typical Weight Loss in Trials* | Other Metabolic Improvements |
|---|---|---|
| Semaglutide | ~12–15% body weight (in obesity trials) PMC+2PMC+2 | Improved glycemic control, reduced fasting insulin, lower hemoglobin A₁c, improved lipid profiles Nature+1 |
| Tirzepatide | Up to ~18-20% in some obesity trials at higher doses PMC+2PMC+2 | Significant lowering of glucose, reduction in waist circumference, improvements in HOMA-IR (insulin resistance) Nature+1 |
*These are approximate, placebo-corrected or compared with lower dose/placebo arms; individual results vary. Real-world results may be somewhat lower, especially if adherence is imperfect. PMC+1
GLP-1 RAs in Women / PCOS
A meta-analysis focused on women with polycystic ovary syndrome (PCOS) showed that GLP-1 RAs, compared to metformin or placebo, significantly reduced:
- BMI and body weight
- Waist circumference, waist-to-hip ratio, abdominal girth
- Fasting insulin, glucose after oral glucose tolerance test, and HOMA-IR (insulin resistance) Nature
These show GLP-1s are effective for women with metabolic disturbances as well.
Cardiovascular Benefits
Beyond weight loss, GLP-1-RA medications have shown major benefits for cardiovascular (CV) outcomes. Key findings include:
- The Semaglutide Cardiovascular Outcomes Trial (STEP / others) has found reduced major adverse cardiovascular events (MACE) — including heart attack, stroke, and CV death — among patients using semaglutide vs placebo. New England Journal of Medicine+1
- Meta-analyses indicate that GLP-1 RAs as a class reduce relative risk of MACE in people with type 2 diabetes, often even in those without overt cardiovascular disease, provided the risk factors are present. Diabetes Journals+2AHA Journals+2
- Mechanisms for CV benefit appear multifactorial: improved lipid profiles (lower LDL, triglycerides; sometimes increased HDL), reduced blood pressure, less inflammation, weight loss (especially visceral fat), improved insulin sensitivity, possible direct effects on vascular function and atherosclerosis progression. ScienceDirect+2New England Journal of Medicine+2
Safety & Side Effects
While the benefits are compelling, safety and tolerability are important. Here’s what research shows:
Common Side Effects
- Gastrointestinal (GI): nausea, diarrhea, constipation, vomiting. These are generally mild-to-moderate and more pronounced during dose escalation. PMC+1
- Early treatment period tends to have more GI side effects; many taper off with time. PMC+1
Less Common / Rare Risks
- Gallbladder issues (cholelithiasis) have been observed in some studies. PMC
- Possible risk of pancreatitis in some, though data remains mixed and incidence is low. PMC+1
- Effects on thyroid C-cells seen in some animal models; human data less clear, and current approved agents have warnings in their labels. Monitoring is usually built in.
- Real-world discontinuation is notable: some studies report 20-50% discontinuation in the first year, often due to side effects, cost, or difficulty with dosing/access. PMC
Considerations for Specific Populations
- Effect on pregnant or breastfeeding women isn’t fully known; typically avoided unless benefit outweighs risk.
- In people with GI disease, or history of pancreatitis or medullary thyroid cancer, special caution required.
Long-Term Benefits & Durability
GLP-1 RAs don’t just produce short-term changes; longer follow-up studies and observational data are compelling:
- Some trials show maintenance of weight loss over 1-2 years when medication is continued and lifestyle changes are sustained. PMC+1
- Improvement in metabolic parameters like fasting insulin and HOMA-IR help reduce risk of developing type 2 diabetes in people who are overweight or glucose intolerant.
- Lowered risk for cardiovascular events as above, which translates into long-term reductions in morbidity and mortality. New England Journal of Medicine+1
- For populations like PCOS, long-term use can help reduce risk of associated metabolic comorbidities (insulin resistance, hepatic steatosis, abnormal lipids) which otherwise contribute to lifetime cardiovascular risk. Nature
What This Means for Patients & What Preston Wellness Recommends
Here are practical takeaways and how we approach GLP-1 therapy safely and effectively:
- Comprehensive Assessment
Before starting, we assess body composition, metabolic risk (lipids, glucose, insulin), cardiovascular history, kidney and liver function. - Start Low, Titrate Slowly
To reduce GI side effects, we begin with lower doses and gradually increase, following approved protocols. - Lifestyle Integration
Nutritional counseling, resistance training, adequate protein, sleep optimization—all enhance and sustain results. - Monitoring & Follow-Up
Regular lab work (glucose, lipids, kidney/liver markers), checking for side effects, dose adjustments. - Duration & Discontinuation Planning
GLP-1 therapy is often long-term. If stopping, must plan transition and risk mitigation (weight regain, metabolic rebound).
Limitations & Open Questions
- Real-world adherence is lower than in trials; many people discontinue or underdose. PMC
- Long-term effects (beyond 3-5 years) on some aspects like bone density, reproductive hormone effects in women, cognition, GI health over decades are still being studied.
- Cost, insurance access, and patient education remain significant barriers to wide adoption.
Conclusion
GLP-1 receptor agonists are among the most exciting developments in metabolic, obesity, and cardiovascular medicine today. With significant evidence showing weight loss, improved glycemic control, and reductions in cardiovascular events, they offer more than just “losing weight.” When used with expert monitoring and personalized care, the safety profile is favorable, and many side effects are manageable.
At Preston Wellness, we believe in using these therapies in a whole-body context: thorough evaluation, tailoring the plan to your health goals, and combining medication with nutrition, hormones, and lifestyle for sustainable, long-term wellness.
Takeaway + Call to Action
If you’re someone who has tried diet and exercise but is still struggling with weight, insulin resistance, or cardiovascular risk factors, GLP-1 therapy may be worth exploring—under medical guidance.
👉 Book a consultation with Preston Wellness to see if GLP-1 therapy is right for you.
📍 Serving Massachusetts & New Hampshire
📞 781-605-8158
🌐 www.prestonwellness.com
Suggested Studies & Sources for Further Reading
- Ghusn W, et al. “GLP-1RAs: Weight Loss Outcomes, Tolerability, Side Effects, and Risks.” PMC article, 2024. PMC
- Lin S, et al. “Efficacy and Safety of GLP-1 receptor agonists on weight and insulin resistance in PCOS.” Nature 2025. Nature
- Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity.” NEJM, 2023. New England Journal of Medicine
- Michos ED, et al. Meta-analysis: GLP-1 RAs and Cardiovascular Risk Reduction. Journal of the American Heart Association, 2023. AHA Journals